Cancer genetic testing and assisted reproduction
Cancer genetic testing and assisted reproduction
复制标题
DOI：
10.1200/jco.2006.06.6100
复制
发表时间：
2006-10-10
影响因子：
45.3
通讯作者：
Davis, Jessica G.
中科院分区：
文献类型：
--
作者：
Offit, Kenneth;Kohut, Kelly;Davis, Jessica G.
由于越来越多的人接受癌症基因检测和提高年轻癌症患者的存活率，包括肿瘤学家在内的卫生保健从业人员将越来越多地被遗传性癌症综合征的家庭成员询问辅助生殖的选择。在这些生殖选择中，植入前遗传学诊断（PGD）提供了选择没有家族性癌症易感突变的胚胎的机会。方法回顾已发表的文献，并对美国PGD中心进行调查。结果基因检测后的产前诊断和/或胚胎选择已在十多种家族性癌症综合征中进行，包括结肠癌和乳腺癌遗传易感性的常见综合征。结论辅助生殖技术虽然为癌症患者家庭提供了新的生殖选择，但其医学适应证和伦理接受度仍有待明确。需要继续讨论PGD在生殖环境中的作用，以便为负责任地使用这些技术以减少遗传性癌症的负担提供信息。
PurposeBecause of increasing uptake of cancer genetic testing and the improving survival of young patients with cancer, health care practitioners including oncologists will increasingly be asked about options for assisted reproduction by members of families affected by hereditary cancer syndromes. Among these reproductive options, preimplantation genetic diagnosis (PGD) offers the opportunity to select embryos without familial cancer-predisposing mutations.MethodsA review of the published literature supplemented by a survey of PGD centers in the United States.ResultsPrenatal diagnosis and/or embryo selection after genetic testing has already been performed in the context of more than a dozen familial cancer syndromes, including the common syndromes of genetic predisposition to colon and breast cancer.ConclusionWhile constituting new reproductive options for families affected by cancer, the medical indications and ethical acceptance of assisted reproductive technologies for adult-onset cancer predisposition syndromes remain to be defined. Continued discussion of the role of PGD in the reproductive setting is needed to inform the responsible use of these technologies to decrease the burden of heritable cancers.